SBIR/STTR Research Award

Novel Gene Repair Technology to Generate Serum Carboxylesterase Deficient Mice

Award identifier fb29c5f988759944e90afc4935a57b638dc32f8fc465c6661039a78f64aacd21Awarding agency Department of Defense · Army

Award amount

$118,173

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Army
Recipient company
VALIGEN, US, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

We propose to use a novel gene repair technology (chimeraplasty) to generate serum carboxylesterase (CaE) deficient mice. Serum CaE acts as an endogenous anti-organophosphate (OPs) bioscavenger that provides mice with inherent protection against OPs.Unlike mice, humans and non-human primates lack serum CaE and are much more susceptible to OP toxicity. The inherent resistance of rodents limits their use as a model system for development of prophylactics that detoxify organophosphate based agents. Atransgenic mouse that lacks serum CaE would provide an inexpensive alternative to non-human primates. Creation of serum CaE deficient mice is proposed by treating embryonic stem cells with chimeric RNA/DNA oligonucleotides (Chimeraplasts) directed atdisrupting the Es-1 gene that encodes CaE in mice. RNA/DNA oligonucleotides have been used (Chimeraplasty) both in vitro and in vivo to correct, mutate, and disrupt genes in systems as diverse as bacterial cells and rodents. Chimeraplasty uses endogenousDNA repair mechanisms and does not introduce foreign DNA or potentially deleterious reporter genes. Once the animals are established they will function as models for the testing of antidotes and establishing the in vivo safety and efficacy of a number ofbioscavenger molecules and to develop prophylactics to eliminate OP toxicity.The availability of a small rodent model will increase the rate of development of antidotes designed to eliminate the toxicity of organophosphate nerve agent exposure. This modelwill provide a high throughput system for establishing the safety and efficacy of a number of different prophylactics. At the present time only expensive primates serve as a reasonable animal model for human toxicity and development of prophylacticsagainst OP based nerve agents. This inexpensive rodent model will dramatically decrease the costs associated with this much needed development. This model will also be of commercial interest to the pesticide business community to help identify means fordetoxification of organophosphorus based pesticide exposure. Of the 25,000 brands of pesticides available in the U.S., most are either organophosphate or carbamate compounds. These compounds are responsible for 80% of the pesticide poisoning in the U.S.The pesticide industry is a $30 billion dollar industry that has been stagnant due to several issues, which include the contemporary awareness to environmental issues. This model system will help to develop less toxic compounds, which will spurn marketgrowth, especially appealing to the residential consumer.

Technology keywords

Not reported

Agency intelligence

Department of Defense

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.